Written by :


Posted on :

February 15, 2023

Kolosis BIO and MTF Biologics Extend Exclusive Agreement

SALT LAKE CITY, Utah, February 14, 2023

(OrthoSpineNews)- Kolosis BIO (Kolosis), a leading provider of orthobiologics solutions, and MTF Biologics, a global tissue processor and nonprofit organization, are proud to announce the extension of their successful partnership. The agreement secures Kolosis BIO’s exclusive rights to market the highly-regarded Kore Fiber and Prime HD bone graft technologies and reinforces the commitment between the organizations to advance patient outcomes and drive industry adoption of superior bone graft technologies.

“We are thrilled to continue our exclusive partnership with MTF Biologics,” said Collin Begley, CEO of Kolosis BIO. “Their proprietary aseptic processing methods and uncompromising commitment to quality align perfectly with our mission to provide patients with the best possible bone grafting options. We look forward to collaborating on new technologies and continuing to make a meaningful impact together in the orthobiologics market.”

“Kolosis BIO’s focus on delivering high-quality bone graft products and expanding their market share make them a valuable partner,” said Brad Bailey, VP & General Manager of Orthopedics at MTF Biologics. “We are excited to continue working together to find new and innovative allograft solutions that will benefit patients and honor the Gift of Donation.”

About Kolosis BIO:

Kolosis BIO is a leading provider of innovative biologic solutions, dedicated to commercializing cutting-edge technologies and delivering market-leading products to the orthopedic industry. As a pure-play biologics company, Kolosis BIO exclusively partners with MTF Biologics to offer superior quality bone graft technologies such as Kore Fiber, a 100% cortical fiber allograft and Prime HD, a pre-hydrated DBM. These allografts are backed by MTF’s proprietary aseptic processing methods that optimally preserve matrix structures and osteoinductive properties.

As the company looks to the future, Kolosis is dedicated to driving innovation in the biologics field, expanding its product offerings and pushing the boundaries of science to enhance patient outcomes. With a focus on relentless execution and bold technologies, Kolosis BIO endeavors to become a leading force in the biologics market. For more information, please visit

About MTF Biologics:

MTF Biologics is a global nonprofit organization that saves and heals lives by honoring donated gifts, serving patients and advancing science. They provide unmatched service, resources, and expertise to donors and their loved ones who give the gift of donation, people who depend on tissue and organ transplants, healthcare providers, and clinicians and scientists.

The International Institute for the Advancement of Medicine (IIAM), a Division of MTF Biologics, honors donors of non-transplantable organs by providing their gifts to the medical research community to combat and cure diseases. Statline, also a Division of MTF Biologics, provides specialized communications and technology expertise to organ, tissue, and eye procurement organizations, as well as the hospitals and patients that they serve. Its sister organization, Deutsches Institute for Zell-und Gewebeersatz – DIZG (The German Institute for Cell and Tissue Transplantation), expands its reach to patients across the globe. For more information, visit